# **UCLA**

# **UCLA Previously Published Works**

#### Title

Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.

### **Permalink**

https://escholarship.org/uc/item/25d0n19z

### **Journal**

Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 65(9)

#### ISSN

1058-4838

#### **Authors**

Byrne, Dana D Tate, Janet P Forde, Kimberly A et al.

### **Publication Date**

2017-10-01

#### DOI

10.1093/cid/cix564

# **Supplemental Material**

https://escholarship.org/uc/item/25d0n19z#supplemental

Peer reviewed

# **SUPPLEMETARY TABLES**

**Supplementary Table 1.** List of International Classification of Diseases, Ninth Revision (ICD-9) diagnoses to identify hospitalization with acute liver injury/decompensation events.

ICD-9 Code	Description		
456.1-456.21	Variceal hemorrhage		
567-567.29 567.8-567.9	Spontaneous bacterial peritonitis		
570	Acute/subacute hepatic necrosis		
572.2	Hepatic coma		
572.3	Ascites		
572.4	Hepatorenal syndrome		
572.8	Liver disease sequelae		
573.3	Toxic (non-infectious) hepatitis		
573.8	Other liver disorder, chemical/drug-induced		
789.5	Ascites		

**Supplementary Table 2**. Propensity score-adjusted relative hazards of acute liver injury outcomes and all-cause mortality in statin initiators compared to statin non-users by HIV and chronic hepatitis C virus (HCV) status among patients with baseline FIB-4 <1.45 (**Supplementary 2a**), FIB-4=1.45-3.25 (**Supplementary 2b**), and FIB-4 >3.25 (**Supplementary 2c**).

**Supplementary Table 2a:** Results among patients with baseline FIB-4 <1.45.

Group	Hazard Ratio of Outcome (95% Confidence Interval)				
	Liver Aminotransferase >200 U/L	Severe ALI*	Hospitalization with ALI	All-Cause Mortality	
HIV/ HCV Coinfected	0.53 (0.33-0.88)	†	0.21 (0.05-0.96)	0.29 (0.17-0.48)	
HCV Monoinfected	0.60 (0.37-0.96)	†	0.12 (0.03-0.54)	0.34 (0.21-0.53)	
HIV Monoinfected	0.43 (0.30-0.61)	0.50 (0.15-1.67)	0.24 (0.10-0.62)	0.20 (0.15-0.26)	
Uninfected	0.81 (0.56-1.12)	0.60 (0.17-2.13)	0.31 (0.13-0.72)	0.21 (0.16-0.27)	

### **Supplementary Table 2b:** Results among patients with baseline FIB-4=1.45-3.25.

Group	Hazard Ratio of Outcome (95% Confidence Interval)				
	Liver Aminotransferase >200 U/L	Severe ALI*	Hospitalization with ALI	All-Cause Mortality	
HIV/ HCV Coinfected	0.96 (0.67-1.38)	0.18 (0.05-0.66)	0.40 (0.19-0.85)	0.56 (0.39-0.80)	
HCV Monoinfected	0.60 (0.40-0.90)	0.16 (0.03-0.81)	0.41 (0.17-1.02)	0.70 (0.46-1.06)	
HIV Monoinfected	0.55 (0.36-0.85)	0.19 (0.06-0.61)	0.11 (0.03-0.33)	0.18 (0.12-0.26)	
Uninfected	0.51 (0.33-0.79)	0.16 (0.06-0.45)	0.19 (0.08-0.47)	0.24 (0.16-0.35)	

## **Supplementary Table 2c**: Results among patients with baseline FIB-4 >3.25.

Group	Hazard Ratio of Outcome (95% Confidence Interval)				
	Liver Aminotransferase >200 U/L	Severe ALI*	Hospitalization with ALI	All-Cause Mortality	
HIV/ HCV Coinfected	0.74 (0.50-1.10)	0.40 (0.17-0.95)	0.53 (0.28-1.03)	0.50 (0.32-0.80)	
HCV Monoinfected	0.87 (0.55-1.38)	0.32 (0.10-0.96)	0.16 (0.05-0.46)	0.54 (0.28-1.03)	
HIV Monoinfected	0.40 (0.17-0.93)	†	0.09 (0.01-0.69)	0.28 (0.15-0.51)	
Uninfected	0.85 (0.37-1.95)	0.10 (0.0.1-0.79)	t	0.33 (0.15-0.77)	

Abbreviations: ALI=acute liver injury; HCV=hepatitis C virus infection

<sup>\*</sup> Severe ALI defined by inpatient or outpatient international normalized ratio []1.5 and serum total bilirubin >2 times upper limit of normal (ULN), with both abnormalities recorded within 30 days of each other.

<sup>†</sup> Indicates too few events to calculate hazard ratios.